Paying for the Orphan Drug System: Break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?

Orphanet Journal of Rare Diseases

Volumn 7, Issue 1, 2012, Pages

  Hughes Wilson, Wills ^a   Palma, Ana ^b   Schuurman, Ad ^c   Simoens, Steven ^d  

^a EU Committee of Experts on Rare Diseases (EUCERD)   (Sweden)

^b Shire Human Genetic Therapies ^*  (Belgium)

^c Business Contact Centre and International Affairs   (Netherlands)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ARTICLE; BUDGET; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG SCREENING; ENZYME REPLACEMENT; EUROPE; FOLLOW UP; GAUCHER DISEASE; GOVERNMENT; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE SYSTEM; HUMAN; RARE DISEASE; REIMBURSEMENT;

COST-BENEFIT ANALYSIS; EUROPE; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 84866564048     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-7-74     Document Type: Article

References (33)

1. European Parliament, Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Official Journal of the European Communities, 22. 1. 2000, L 18/1-5 http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en: PDF ],22.01.2000
2. Community Register http://ec.europa.eu/health/documents/community- register/html/index-en.htm, Orphanet: http://www.orpha.net/consor/cgi-bin/Drugs- ListOrphanDrugs.php?lng=EN
3. Press release inaugural meeting of the Committee for Orphan Medicinal Products (EMEA/COMP/5/00), Status report on the implementation of the European Parliament legislation on Orphan Medicinal Products (EMEA/738/01/EN)
4. EURORDIS statement http://www.eurordis.org/content/celebrating-10-years- orphan-drug-regulation-europe; Joint EBE and EuropaBio statement: http://www.europabio.org/healthcare/press/ebe-and-europabio-hail-eu-orphan- medicinal-products-regulation-success
5. Orphan legislation does more good than harm, 7 December 2010, Rapid response to Article "The problem of orphan drugs. Hall A, 341 2010 c6456 Published 16 November 2010," [ http://www.bmj.com/content/341/bmj.c6456? tab=responses ]
6. Orphan drugs for rare diseases: grounds for special status. Picavet E, Dooms M, Cassiman D, Simoens S, Drug Develop Res in press
7. For Belgium: law of 10 June 2006 (state aid authorised by the EU until 31/12/2013) http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2008:229: 0005:0008:EN:PDF. For France, other tax exemption authorised by EU in 2002 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2002:284:0002:0002: EN:PDF
8. German AMNOG, E.g., exemption from standard economic evaluation in Belgium and the Netherlands; German AMNOG, which exempts orphan drugs with sales of less than 50 million Euros per year from being subject to an "additional benefit" dossier http://www.english.g-ba.de/ benefitassessment/information
9. European Parliament, Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products", Official Journal of the European Communities, 22. 1. 2000, L 18/5 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001: 0005:en:PDF, 22.01.2000
10. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. Denis, et al. J Med Eco 2010 2 295 301
11. Policies for Rare Diseases and Orphan Drugs. KCE Report 112C" 2009, Also published as: Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. "Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. Belgian Federal Centre for Healthcare Belgian Health Care Knowledge Centre, J Med Econ 2010 13 2 295 301 10.3111/13696998.2010.491427 20482245
12. ALCIMED, Study on orphan drugs 2004 Phase I, 2004 http://ec.europa.eu/ health/files/orphanmp/doc/pricestudy/final-final-report-part-1-web-en.pdf
13. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Orofino, et al. Appl Health Econ Health Policy 2010 8 5
14. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Carina S, Tsveta M, Adam H, Orphanet J Rare Dis 2011 6 62 10.1186/1750-1172-6-62 21951518
15. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Trusheim MR, Berndt ER, Douglas FL, Nat Rev Drug Discov 2007 6 4 287 293 10.1038/nrd2251 17380152 (Pubitemid 46505879)
16. EURORDIS statement, Orphan drugs: rising to the challenge to ensure a better future for 30 million patients in Europe 2009 http://www.eurordis.org/ sites/default/files/publications/Statement-Future-of-Orphan-Drugs-14-October-09. pdf
17. Orphan drug pricing may warrant a competition law investigation. Roos JC, Hyry HI, Cox TM, BMJ 2010 341 published 16 November 2010 10.1136/bmj.c6471
18. Pricing & Reimbursement of Orphan Drugs: the need for more transparency. Simoens S, Orphanet J Rare Dis 2011 6 42 17 June 2011 10.1186/1750-1172-6-42 21682893
19. European Commission, Research and Innovation-Health, International Rare Diseases Research Consortium http://ec.europa.eu/research/health/medical- research/rare-diseases/irdirc-en.html
20. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Attina T, Camidge R, Newby DE, Webb DJ, Heart 2005 91 6 825 831 10.1136/hrt.2004.053991 15894792 (Pubitemid 40769240)
21. What price do we pay for repurposing medicines for rare diseases? Simoens S, Picavet E, Cassiman D, Dooms M, Brit Med J 2012 4th January 2012 http://www.bmj.com/rapid-response/2011/11/27/re-orphan-diseases-which-ones-do- we-adopt
22. Open letter to Prime Minister David Cameron and health secretary Andrew Lansley. Nicholl DJ, Hilton-Jones D, Palace J, Richmond S, Finlayson S, Winer J, Weir A, Maddison P, Fletcher N, Sussman J, Silver N, Nixon J, Kullmann D, Embleton N, Beeson D, Farrugia ME, Hill M, McDermott C, Llewelyn G, Leonard J, Morris M, BMJ 2010 16 341 c6466. doi:10.1136/bmj.c6466
23. Internal Medicine News Digital Network-Women's Health. Smith J, Makena Price Spike Causes Anger, Fear 2011
24. Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs. Simoens S, Cassiman D, Picavet E, Dooms M, Drugs Ther Perspect 2011 27 10 24 26 10.2165/11601640-000000000-00000
25. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, O'Hagan A, Moore D, Health Technol Asses 2006 10 24
26. Assessing the economic challenges posed by orphan drugs. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J, Int J Technol Assess Health Care 2007 23 1 36 42 17234015 (Pubitemid 46648298)
27. National Institute for Health and Clinical Excellence (NICE), Appraising Orphan Drugs http://www.nice.org.uk/niceMedia/pdf/smt/120705item4.pdf (DRAFT v3)
28. Priority setting of health interventions: the need for multi-criteria decision analysis. Baltussen R, Niessen L, Cost Eff Resour Alloc 2006 4 14 10.1186/1478-7547-4-14 16923181 (Pubitemid 44377737)
29. Social economic burden and health related quality of life in patients with rare diseases in Europe http://www.burqol-rd.com/index.html
30. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Article 3(1)(a) European Parliament, Off J Eur Communities 2000 L18 2 3 http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF, 22.01.2000
31. Lange S, IQWiG's approach in Germany Presentation at European Conference on Rare Diseases & Orphan Drugs 2012 http://www.rare-diseases.eu/2012/ Second-Day-Programme 23237499
32. The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? Wellman-Labadie O, Zhou Y, Health Policy 2009 95 2-3 216 228 Epub 2009 Dec 29 20036435
33. E.g., the potential connection between Gaucher Disease and Parkinson's Disease http://www.nejm.org/doi/full/10.1056/NEJMoa033277